2021
DOI: 10.1016/j.oooo.2020.03.044
|View full text |Cite
|
Sign up to set email alerts
|

Osteosarcoma of the jaw: report of 3 cases (including the rare epithelioid variant) with review of literature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
11
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(12 citation statements)
references
References 41 publications
1
11
0
Order By: Relevance
“…Other predisposing factors such as ossifying fibroma must be taken into account [7]. In our study we observed the presence of an initial lesion diagnosed as ossifying fibroma that after 5 years debuted as chondroblastic OSJ.…”
Section: Discussionsupporting
confidence: 47%
See 3 more Smart Citations
“…Other predisposing factors such as ossifying fibroma must be taken into account [7]. In our study we observed the presence of an initial lesion diagnosed as ossifying fibroma that after 5 years debuted as chondroblastic OSJ.…”
Section: Discussionsupporting
confidence: 47%
“…It is identified radiologically as poorly defined lytic lesions with the ability to show a periosteal reaction [38]. The presence of osteoid is a fundamental requirement for its diagnosis, although the amount present can be variable [7]. In our study, two cases were recorded with this morphological pattern in which an extensive neoformation of osteoid in socket was identified in close contact with the tumor cellularity.…”
Section: Discussionmentioning
confidence: 66%
See 2 more Smart Citations
“…A review of the current reveals a general consensus on the prevalence of high-grade OSM, with prevalence rates ranging from 50 to 96% [17,18]. This variability was confirmed by Malik et al [19] in 2020, who reviewed all previous reports describing series of more than 10 patients with OSJ. In a review article, Shah et al reported incidences of about 80% for the high-grade variant and less than 2% for low-grade tumors.…”
Section: Key Pointsmentioning
confidence: 93%